drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00402 | DB12267 | 1,407 | 1,476 | [
"DDInter685",
"DDInter233"
] | Eszopiclone | Brigatinib | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1407,
24,
1476
]
],
[
[
1407,
24,
918
],
[
918,
24,
1476
]
],
[
[
1407,
24,
982
],
[
982,
63,
1476
]
],
[
[
1407,
64,
475
],
[
475,
... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and ... |
DB00099 | DB15035 | 440 | 503 | [
"DDInter735",
"DDInter1959"
] | Filgrastim | Zanubrutinib | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Moderate | 1 | [
[
[
440,
24,
503
]
],
[
[
440,
24,
951
],
[
951,
24,
503
]
],
[
[
440,
63,
599
],
[
599,
24,
503
]
],
[
[
440,
24,
39
],
[
39,
25,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and A... |
DB00388 | DB01168 | 1,636 | 1,053 | [
"DDInter1453",
"DDInter1526"
] | Phenylephrine | Procarbazine | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
1636,
25,
1053
]
],
[
[
1636,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1636,
63,
1000
],
[
1000,
24,
1053
]
],
[
[
1636,
24,
480
],
[
4... | [
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Phenylephrine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v}... | Phenylephrine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel and Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Pro... |
DB00539 | DB01177 | 11 | 77 | [
"DDInter1837",
"DDInter904"
] | Toremifene | Idarubicin | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Major | 2 | [
[
[
11,
25,
77
]
],
[
[
11,
5,
11579
],
[
11579,
44,
77
]
],
[
[
11,
7,
6952
],
[
6952,
46,
77
]
],
[
[
11,
18,
10780
],
[
10780,
57... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
],
[
[
"Toremifene",
"{u} (Compound) treats {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is treated by {v} (Com... | Toremifene (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Idarubicin (Compound)
Toremifene (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Idarubicin (Compound)
Toremifene (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Idarubicin ... |
DB00808 | DB13928 | 1,605 | 1,385 | [
"DDInter916",
"DDInter1660"
] | Indapamide | Semaglutide | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1605,
24,
1385
]
],
[
[
1605,
24,
891
],
[
891,
24,
1385
]
],
[
[
1605,
40,
811
],
[
811,
24,
1385
]
],
[
[
1605,
63,
1144
],
[
1144,
... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[... | Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Indapamide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that ... |
DB00497 | DB12267 | 828 | 1,476 | [
"DDInter1366",
"DDInter233"
] | Oxycodone | Brigatinib | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
828,
24,
1476
]
],
[
[
828,
63,
1184
],
[
1184,
24,
1476
]
],
[
[
828,
24,
951
],
[
951,
24,
1476
]
],
[
[
828,
25,
1250
],
[
1250,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib... |
DB00445 | DB15066 | 322 | 445 | [
"DDInter655",
"DDInter821"
] | Epirubicin | Givosiran | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Moderate | 1 | [
[
[
322,
24,
445
]
],
[
[
322,
24,
1555
],
[
1555,
24,
445
]
],
[
[
322,
63,
482
],
[
482,
24,
445
]
],
[
[
322,
64,
702
],
[
702,
2... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tiogu... |
DB00975 | DB01240 | 1,317 | 885 | [
"DDInter573",
"DDInter657"
] | Dipyridamole | Epoprostenol | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1317,
24,
885
]
],
[
[
1317,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1317,
21,
28684
],
[
28684,
60,
885
]
],
[
[
1317,
23,
539
],
[
539,
... | [
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Dipyridamole (Compound) causes Hypoaesthesia (Side Effect) and Hypoaesthesia (Side Effect) is caused by Epoprostenol (Compound)
Dipyridamole may cause a... |
DB00518 | DB01058 | 510 | 978 | [
"DDInter35",
"DDInter1510"
] | Albendazole | Praziquantel | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Minor | 0 | [
[
[
510,
23,
978
]
],
[
[
510,
6,
7950
],
[
7950,
45,
978
]
],
[
[
510,
21,
28680
],
[
28680,
60,
978
]
],
[
[
510,
62,
752
],
[
752,
... | [
[
[
"Albendazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Praziquantel"
]
],
[
[
"Albendazole",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)... | Albendazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Praziquantel (Compound)
Albendazole (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Praziquantel (Compound)
Albendazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidin... |
DB00834 | DB13074 | 932 | 877 | [
"DDInter1215",
"DDInter1110"
] | Mifepristone | Macimorelin | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
932,
25,
877
]
],
[
[
932,
23,
112
],
[
112,
23,
877
]
],
[
[
932,
24,
1320
],
[
1320,
24,
877
]
],
[
[
932,
25,
913
],
[
913,
2... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Mifepristone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and E... |
DB06589 | DB08865 | 1,250 | 1,593 | [
"DDInter1400",
"DDInter448"
] | Pazopanib | Crizotinib | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1250,
25,
1593
]
],
[
[
1250,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1250,
18,
7580
],
[
7580,
45,
1593
]
],
[
[
1250,
18,
6917
],
[
691... | [
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Pazopanib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotini... | Pazopanib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Pazopanib (Compound) downregulates TESK1 (Gene) and TESK1 (Gene) is bound by Crizotinib (Compound)
Pazopanib (Compound) downregulates SNX13 (Gene) and SNX13 (Gene) is upregulated by Crizotinib (Compound)
Pazopanib (Compound) up... |
DB04948 | DB06691 | 1,084 | 849 | [
"DDInter1083",
"DDInter1155"
] | Lofexidine | Mepyramine | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1084,
24,
849
]
],
[
[
1084,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1084,
24,
407
],
[
407,
63,
849
]
],
[
[
1084,
40,
1617
],
[
1617,
... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may c... |
DB01197 | DB01261 | 1,603 | 170 | [
"DDInter292",
"DDInter1679"
] | Captopril | Sitagliptin | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
1603,
24,
170
]
],
[
[
1603,
6,
4973
],
[
4973,
45,
170
]
],
[
[
1603,
21,
28921
],
[
28921,
60,
170
]
],
[
[
1603,
24,
708
],
[
708,
... | [
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Captopril",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Captopril (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sitagliptin (Compound)
Captopril (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sitagliptin (Compound)
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Cort... |
DB00619 | DB04911 | 1,419 | 968 | [
"DDInter909",
"DDInter1347"
] | Imatinib | Oritavancin | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts... | Moderate | 1 | [
[
[
1419,
24,
968
]
],
[
[
1419,
21,
29293
],
[
29293,
60,
968
]
],
[
[
1419,
25,
126
],
[
126,
24,
968
]
],
[
[
1419,
25,
1476
],
[
1476,... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oritavancin"
]
],
[
[
"Imatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Leukocytoclastic vasculitis"
],
[
"Leukocytoclastic vasculitis",... | Imatinib (Compound) causes Leukocytoclastic vasculitis (Side Effect) and Leukocytoclastic vasculitis (Side Effect) is caused by Oritavancin (Compound)
Imatinib may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when take... |
DB00501 | DB01118 | 752 | 33 | [
"DDInter380",
"DDInter76"
] | Cimetidine | Amiodarone | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Moderate | 1 | [
[
[
752,
24,
33
]
],
[
[
752,
24,
540
],
[
540,
1,
33
]
],
[
[
752,
6,
7950
],
[
7950,
45,
33
]
],
[
[
752,
21,
29005
],
[
29005,
60... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Cimetidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Amiodarone (Compound)
Cimetidine (Compound) causes Dermatitis exfoliative (Side Effect... |
DB04855 | DB09104 | 540 | 286 | [
"DDInter602",
"DDInter1118"
] | Dronedarone | Magnesium hydroxide | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
540,
24,
286
]
],
[
[
540,
64,
820
],
[
820,
23,
286
]
],
[
[
540,
63,
752
],
[
752,
23,
286
]
],
[
[
540,
24,
263
],
[
263,
23,... | [
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
... | Dronedarone may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine... |
DB00615 | DB05239 | 690 | 866 | [
"DDInter1589",
"DDInter425"
] | Rifabutin | Cobimetinib | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Major | 2 | [
[
[
690,
25,
866
]
],
[
[
690,
24,
214
],
[
214,
63,
866
]
],
[
[
690,
24,
888
],
[
888,
24,
866
]
],
[
[
690,
25,
1478
],
[
1478,
6... | [
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobimetinib"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamati... | Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamo... |
DB00564 | DB08896 | 1,236 | 292 | [
"DDInter293",
"DDInter1576"
] | Carbamazepine | Regorafenib | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
1236,
24,
292
]
],
[
[
1236,
63,
79
],
[
79,
1,
292
]
],
[
[
1236,
6,
6017
],
[
6017,
45,
292
]
],
[
[
1236,
21,
29429
],
[
29429,
... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Carbamazepine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Carbamazepine (Compound) causes Infestation NOS (Side Effect... |
DB00757 | DB01396 | 1,166 | 1,482 | [
"DDInter581",
"DDInter553"
] | Dolasetron | Digitoxin | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Major | 2 | [
[
[
1166,
25,
1482
]
],
[
[
1166,
64,
1252
],
[
1252,
1,
1482
]
],
[
[
1166,
6,
8374
],
[
8374,
45,
1482
]
],
[
[
1166,
7,
6952
],
[
6952,... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Digitoxin"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} (Compoun... | Dolasetron may lead to a major life threatening interaction when taken with Digoxin and Digoxin (Compound) resembles Digitoxin (Compound)
Dolasetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Digitoxin (Compound)
Dolasetron (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Digit... |
DB00341 | DB00690 | 1,242 | 1,216 | [
"DDInter343",
"DDInter762"
] | Cetirizine | Flurazepam | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | A benzodiazepine derivative used mainly as a hypnotic. | Moderate | 1 | [
[
[
1242,
24,
1216
]
],
[
[
1242,
24,
1418
],
[
1418,
1,
1216
]
],
[
[
1242,
24,
481
],
[
481,
40,
1216
]
],
[
[
1242,
63,
1174
],
[
1174,... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Flurazepam (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam (Compound) resembles Flurazepam (Compound)
Cetiri... |
DB00662 | DB00831 | 717 | 1,178 | [
"DDInter1873",
"DDInter1866"
] | Trimethobenzamide | Trifluoperazine | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Moderate | 1 | [
[
[
717,
24,
1178
]
],
[
[
717,
63,
695
],
[
695,
40,
1178
]
],
[
[
717,
24,
146
],
[
146,
40,
1178
]
],
[
[
717,
24,
1630
],
[
1630,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapin... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine (Compound) resembles T... |
DB09038 | DB12010 | 1,450 | 214 | [
"DDInter636",
"DDInter785"
] | Empagliflozin | Fostamatinib | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1450,
24,
214
]
],
[
[
1450,
63,
1428
],
[
1428,
24,
214
]
],
[
[
1450,
24,
1155
],
[
1155,
24,
214
]
],
[
[
1450,
24,
1017
],
[
1017,... | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
... | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib and... |
DB00377 | DB00675 | 1,494 | 888 | [
"DDInter1382",
"DDInter1744"
] | Palonosetron | Tamoxifen | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
1494,
24,
888
]
],
[
[
1494,
24,
675
],
[
675,
25,
888
]
],
[
[
1494,
24,
543
],
[
543,
63,
888
]
],
[
[
1494,
6,
12523
],
[
12523,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Lo... |
DB05273 | DB13985 | 507 | 546 | [
"DDInter1638",
"DDInter1108"
] | Samarium (153Sm) lexidronam | Lutetium Lu 177 dotatate | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Major | 2 | [
[
[
507,
25,
546
]
],
[
[
507,
24,
270
],
[
270,
24,
546
]
],
[
[
507,
64,
1555
],
[
1555,
24,
546
]
],
[
[
507,
25,
384
],
[
384,
2... | [
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Samarium (153Sm) lexidronam may lead to a major life threatening interaction wh... |
DB00574 | DB11640 | 121 | 1,267 | [
"DDInter717",
"DDInter64"
] | Fenfluramine | Amifampridine | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations . It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscul... | Moderate | 1 | [
[
[
121,
24,
1267
]
],
[
[
121,
24,
1264
],
[
1264,
24,
1267
]
],
[
[
121,
25,
1039
],
[
1039,
24,
1267
]
],
[
[
121,
64,
1466
],
[
1466,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Fenfluramine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dex
Fenfluramin... |
DB00035 | DB00215 | 1,314 | 1,230 | [
"DDInter507",
"DDInter388"
] | Desmopressin | Citalopram | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Moderate | 1 | [
[
[
1314,
24,
1230
]
],
[
[
1314,
24,
318
],
[
318,
40,
1230
]
],
[
[
1314,
21,
28900
],
[
28900,
60,
1230
]
],
[
[
1314,
24,
1574
],
[
15... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
],
... | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) resembles Citalopram (Compound)
Desmopressin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Citalopram (Compound)
Desmopressin may cause a m... |
DB01050 | DB01172 | 848 | 416 | [
"DDInter900",
"DDInter1004"
] | Ibuprofen | Kanamycin | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
848,
24,
416
]
],
[
[
848,
6,
7720
],
[
7720,
46,
416
]
],
[
[
848,
21,
31264
],
[
31264,
60,
416
]
],
[
[
848,
63,
1252
],
[
1252,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Ibuprofen",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)"... | Ibuprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Kanamycin (Compound)
Ibuprofen (Compound) causes Nephrotoxicity (Side Effect) and Nephrotoxicity (Side Effect) is caused by Kanamycin (Compound)
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Digoxin an... |
DB00712 | DB00912 | 1,274 | 473 | [
"DDInter763",
"DDInter1581"
] | Flurbiprofen | Repaglinide | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
1274,
24,
473
]
],
[
[
1274,
6,
1829
],
[
1829,
45,
473
]
],
[
[
1274,
21,
28873
],
[
28873,
60,
473
]
],
[
[
1274,
24,
336
],
[
336,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
... | Flurbiprofen (Compound) binds ALB (Gene) and ALB (Gene) is bound by Repaglinide (Compound)
Flurbiprofen (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Repaglinide (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine ... |
DB00593 | DB00835 | 1,464 | 100 | [
"DDInter695",
"DDInter245"
] | Ethosuximide | Brompheniramine | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
1464,
24,
100
]
],
[
[
1464,
24,
832
],
[
832,
24,
100
]
],
[
[
1464,
63,
128
],
[
128,
24,
100
]
],
[
[
1464,
24,
649
],
[
649,
... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Dexb... |
DB00280 | DB00835 | 494 | 100 | [
"DDInter575",
"DDInter245"
] | Disopyramide | Brompheniramine | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
494,
24,
100
]
],
[
[
494,
35,
832
],
[
832,
24,
100
]
],
[
[
494,
24,
128
],
[
128,
24,
100
]
],
[
[
494,
40,
11244
],
[
11244,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases whe... | Disopyramide (Compound) resembles Tripelennamine (Compound) and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Disopyramide may cause a moderate... |
DB01043 | DB01176 | 108 | 537 | [
"DDInter1146",
"DDInter453"
] | Memantine | Cyclizine | Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in ... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
108,
24,
537
]
],
[
[
108,
24,
1511
],
[
1511,
63,
537
]
],
[
[
108,
63,
104
],
[
104,
1,
537
]
],
[
[
108,
24,
830
],
[
830,
1,... | [
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Memantine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
... | Memantine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Memantine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methd... |
DB00852 | DB01067 | 1,445 | 959 | [
"DDInter1545",
"DDInter826"
] | Pseudoephedrine | Glipizide | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1445,
24,
959
]
],
[
[
1445,
63,
245
],
[
245,
40,
959
]
],
[
[
1445,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1445,
21,
28698
],
[
28698,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
]... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide... |
DB00398 | DB01234 | 79 | 1,220 | [
"DDInter1702",
"DDInter513"
] | Sorafenib | Dexamethasone | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
79,
24,
1220
]
],
[
[
79,
6,
21998
],
[
21998,
45,
1220
]
],
[
[
79,
7,
3163
],
[
3163,
46,
1220
]
],
[
[
79,
18,
3154
],
[
3154,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound ... | Sorafenib (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Dexamethasone (Compound)
Sorafenib (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Dexamethasone (Compound)
Sorafenib (Compound) downregulates SRSF2 (Gene) and SRSF2 (Gene) is upregulated by Dexamethasone... |
DB00333 | DB00692 | 576 | 274 | [
"DDInter1166",
"DDInter1448"
] | Methadone | Phentolamine | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Moderate | 1 | [
[
[
576,
24,
274
]
],
[
[
576,
1,
11288
],
[
11288,
1,
274
]
],
[
[
576,
21,
29118
],
[
29118,
60,
274
]
],
[
[
576,
24,
530
],
[
530,
... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Antazoline"
],
[
"Antazoline",
"{u} (Compound) resemble... | Methadone (Compound) resembles Antazoline (Compound) and Antazoline (Compound) resembles Phentolamine (Compound)
Methadone (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Phentolamine (Compound)
Methadone may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00704 | DB00982 | 267 | 1,517 | [
"DDInter1263",
"DDInter991"
] | Naltrexone | Isotretinoin | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Moderate | 1 | [
[
[
267,
24,
1517
]
],
[
[
267,
63,
640
],
[
640,
25,
1517
]
],
[
[
267,
18,
6168
],
[
6168,
46,
1517
]
],
[
[
267,
7,
3163
],
[
3163,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acitretin"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may lead to a major life threatening interaction when taken with Isotretinoin
Naltrexone (Compound) downregulates IGFBP3 (Gene) and IGFBP3 (Gene) is upregulated by Isotretinoin (Compound)
Naltrexone (Compo... |
DB08895 | DB14811 | 976 | 385 | [
"DDInter1825",
"DDInter979"
] | Tofacitinib | Isatuximab | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Major | 2 | [
[
[
976,
25,
385
]
],
[
[
976,
25,
1362
],
[
1362,
24,
385
]
],
[
[
976,
64,
377
],
[
377,
24,
385
]
],
[
[
976,
24,
810
],
[
810,
2... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isatuximab"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may... | Tofacitinib may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Tofacitinib may lead to a major life threatening interaction when taken with Mitomycin and Mitomycin may cause a moderate interact... |
DB06186 | DB14761 | 1,439 | 242 | [
"DDInter969",
"DDInter1578"
] | Ipilimumab | Remdesivir | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
1439,
24,
242
]
],
[
[
1439,
63,
467
],
[
467,
24,
242
]
],
[
[
1439,
64,
1377
],
[
1377,
24,
242
]
],
[
[
1439,
24,
384
],
[
384,
... | [
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
... | Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Ipilimumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may ca... |
DB00275 | DB01069 | 217 | 401 | [
"DDInter1330",
"DDInter1533"
] | Olmesartan | Promethazine | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
217,
24,
401
]
],
[
[
217,
24,
1264
],
[
1264,
63,
401
]
],
[
[
217,
24,
104
],
[
104,
24,
401
]
],
[
[
217,
21,
28709
],
[
28709,
... | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdila... |
DB00612 | DB06691 | 1,121 | 849 | [
"DDInter216",
"DDInter1155"
] | Bisoprolol | Mepyramine | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1121,
24,
849
]
],
[
[
1121,
6,
12523
],
[
12523,
45,
849
]
],
[
[
1121,
24,
770
],
[
770,
24,
849
]
],
[
[
1121,
1,
88
],
[
88,
... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Bisoprolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",... | Bisoprolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Bisoprolol (Comp... |
DB00059 | DB01076 | 1,560 | 700 | [
"DDInter1404",
"DDInter133"
] | Pegaspargase | Atorvastatin | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Moderate | 1 | [
[
[
1560,
24,
700
]
],
[
[
1560,
24,
788
],
[
788,
1,
700
]
],
[
[
1560,
24,
303
],
[
303,
23,
700
]
],
[
[
1560,
24,
578
],
[
578,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Atorvastatin (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate... |
DB00001 | DB14276 | 1,578 | 1,631 | [
"DDInter1037",
"DDInter1892"
] | Lepirudin | Turmeric | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
1578,
23,
1631
]
],
[
[
1578,
25,
20
],
[
20,
23,
1631
]
],
[
[
1578,
24,
1479
],
[
1479,
23,
1631
]
],
[
[
1578,
25,
20
],
[
20,
... | [
[
[
"Lepirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",... | Lepirudin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicyl... |
DB01259 | DB06595 | 392 | 1,491 | [
"DDInter1024",
"DDInter1214"
] | Lapatinib | Midostaurin | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
392,
24,
1491
]
],
[
[
392,
23,
1135
],
[
1135,
62,
1491
]
],
[
[
392,
62,
112
],
[
112,
23,
1491
]
],
[
[
392,
24,
761
],
[
761,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Lapatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazol... |
DB08904 | DB15233 | 375 | 1,650 | [
"DDInter342",
"DDInter142"
] | Certolizumab pegol | Avapritinib | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
375,
25,
1650
]
],
[
[
375,
64,
1101
],
[
1101,
24,
1650
]
],
[
[
375,
63,
58
],
[
58,
24,
1650
]
],
[
[
375,
25,
270
],
[
270,
... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarote... | Certolizumab pegol may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefa... |
DB00009 | DB08816 | 1,271 | 578 | [
"DDInter56",
"DDInter1802"
] | Alteplase | Ticagrelor | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1271,
24,
578
]
],
[
[
1271,
23,
297
],
[
297,
62,
578
]
],
[
[
1271,
24,
191
],
[
191,
23,
578
]
],
[
[
1271,
64,
1578
],
[
1578,
... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Alteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clov... | Alteplase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Aminocaproic acid and Aminocaproic ac... |
DB00312 | DB00366 | 1,023 | 1,594 | [
"DDInter1423",
"DDInter600"
] | Pentobarbital | Doxylamine | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Moderate | 1 | [
[
[
1023,
24,
1594
]
],
[
[
1023,
24,
11
],
[
11,
1,
1594
]
],
[
[
1023,
24,
662
],
[
662,
63,
1594
]
],
[
[
1023,
18,
18226
],
[
18226,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene (Compound) resembles Doxylamine (Compound)
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interactio... |
DB01028 | DB09134 | 1,332 | 1,552 | [
"DDInter1179",
"DDInter966"
] | Methoxyflurane | Ioversol | An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular... | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Major | 2 | [
[
[
1332,
25,
1552
]
],
[
[
1332,
24,
848
],
[
848,
25,
1552
]
],
[
[
1332,
63,
1274
],
[
1274,
25,
1552
]
],
[
[
1332,
64,
629
],
[
629,
... | [
[
[
"Methoxyflurane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Methoxyflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibupr... | Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Ioversol
Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen ma... |
DB05812 | DB12141 | 1,374 | 971 | [
"DDInter8",
"DDInter817"
] | Abiraterone | Gilteritinib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1374,
24,
971
]
],
[
[
1374,
23,
1135
],
[
1135,
23,
971
]
],
[
[
1374,
62,
1247
],
[
1247,
23,
971
]
],
[
[
1374,
23,
466
],
[
466,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Abiraterone may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulf... |
DB00398 | DB01255 | 79 | 633 | [
"DDInter1702",
"DDInter1078"
] | Sorafenib | Lisdexamfetamine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Moderate | 1 | [
[
[
79,
24,
633
]
],
[
[
79,
21,
28890
],
[
28890,
60,
633
]
],
[
[
79,
23,
112
],
[
112,
23,
633
]
],
[
[
79,
63,
1494
],
[
1494,
2... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
]
],
[
[
"Sorafenib",
"{u} (Compound) causes {v} (Side Effect)",
"Myocardial infarction"
],
[
"Myocardial infarction",
... | Sorafenib (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Lisdexamfetamine (Compound)
Sorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical e... |
DB00682 | DB08918 | 126 | 41 | [
"DDInter1951",
"DDInter1059"
] | Warfarin | Levomilnacipran | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
126,
24,
41
]
],
[
[
126,
24,
901
],
[
901,
40,
41
]
],
[
[
126,
6,
10215
],
[
10215,
45,
41
]
],
[
[
126,
25,
498
],
[
498,
63,... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Warfarin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Levomilnacipran (Compound)
Warfarin may lead to a major life threatening interactio... |
DB00620 | DB00938 | 175 | 455 | [
"DDInter1855",
"DDInter1635"
] | Triamcinolone | Salmeterol | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Minor | 0 | [
[
[
175,
23,
455
]
],
[
[
175,
63,
1523
],
[
1523,
25,
455
]
],
[
[
175,
23,
688
],
[
688,
63,
455
]
],
[
[
175,
5,
11649
],
[
11649,
... | [
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Salmeterol
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may caus... |
DB00637 | DB00776 | 1,557 | 1,335 | [
"DDInter128",
"DDInter1360"
] | Astemizole | Oxcarbazepine | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Moderate | 1 | [
[
[
1557,
24,
1335
]
],
[
[
1557,
24,
1264
],
[
1264,
63,
1335
]
],
[
[
1557,
23,
307
],
[
307,
1,
1335
]
],
[
[
1557,
63,
21
],
[
21,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine
Astemizole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (C... |
DB00496 | DB09272 | 194 | 412 | [
"DDInter480",
"DDInter632"
] | Darifenacin | Eluxadoline | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
194,
24,
412
]
],
[
[
194,
63,
1594
],
[
1594,
24,
412
]
],
[
[
194,
24,
543
],
[
543,
24,
412
]
],
[
[
194,
40,
1413
],
[
1413,
... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Lop... |
DB01294 | DB11130 | 266 | 407 | [
"DDInter215",
"DDInter1344"
] | Bismuth subsalicylate | Opium | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth s... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
266,
24,
407
]
],
[
[
266,
63,
1347
],
[
1347,
24,
407
]
],
[
[
266,
24,
578
],
[
578,
24,
407
]
],
[
[
266,
63,
1347
],
[
1347,
... | [
[
[
"Bismuth subsalicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Bismuth subsalicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogre... | Bismuth subsalicylate may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Opium
Bismuth subsalicylate may cause a moderate interaction that could exacerbate diseases when taken with Ti... |
DB00622 | DB00741 | 1,081 | 167 | [
"DDInter1287",
"DDInter885"
] | Nicardipine | Hydrocortisone | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1081,
24,
167
]
],
[
[
1081,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1081,
63,
175
],
[
175,
40,
167
]
],
[
[
1081,
24,
870
],
[
870,
... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],... | Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Hydr... |
DB00678 | DB08912 | 240 | 1,040 | [
"DDInter1095",
"DDInter462"
] | Losartan | Dabrafenib | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
240,
24,
1040
]
],
[
[
240,
6,
13478
],
[
13478,
45,
1040
]
],
[
[
240,
7,
3727
],
[
3727,
46,
1040
]
],
[
[
240,
7,
8587
],
[
8587,
... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Losartan",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B3"
],
[
"SLCO1B3",
"{u} (Gene) is bound by {v} (Compound)",
... | Losartan (Compound) binds SLCO1B3 (Gene) and SLCO1B3 (Gene) is bound by Dabrafenib (Compound)
Losartan (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Dabrafenib (Compound)
Losartan (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is downregulated by Dabrafenib (Compound)
Losartan (Compound) causes... |
DB08896 | DB08916 | 292 | 26 | [
"DDInter1576",
"DDInter32"
] | Regorafenib | Afatinib | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Moderate | 1 | [
[
[
292,
24,
26
]
],
[
[
292,
6,
4973
],
[
4973,
45,
26
]
],
[
[
292,
54,
19212
],
[
19212,
15,
26
]
],
[
[
292,
21,
28809
],
[
28809,
... | [
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Regorafenib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Regorafenib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Afatinib (Compound)
Regorafenib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class) and Protein Kinase Inhibitors (Pharmacologic Class) includes Afatinib (Compound)
Regorafenib (Compound) causes Diarrhoea (Side Effect) and Diar... |
DB01138 | DB06697 | 804 | 436 | [
"DDInter1726",
"DDInter121"
] | Sulfinpyrazone | Artemether | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</... | Moderate | 1 | [
[
[
804,
24,
436
]
],
[
[
804,
6,
6017
],
[
6017,
45,
436
]
],
[
[
804,
24,
214
],
[
214,
63,
436
]
],
[
[
804,
62,
1101
],
[
1101,
... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Artemether"
]
],
[
[
"Sulfinpyrazone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Com... | Sulfinpyrazone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Artemether (Compound)
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Artemether
Sulfin... |
DB00627 | DB01067 | 265 | 959 | [
"DDInter1286",
"DDInter826"
] | Niacin | Glipizide | Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
265,
24,
959
]
],
[
[
265,
63,
245
],
[
245,
40,
959
]
],
[
[
265,
24,
1411
],
[
1411,
1,
959
]
],
[
[
265,
21,
29442
],
[
29442,
... | [
[
[
"Niacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Niacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Gli... | Niacin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
Niacin... |
DB00065 | DB09061 | 581 | 1,627 | [
"DDInter923",
"DDInter284"
] | Infliximab | Cannabidiol | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
581,
24,
1627
]
],
[
[
581,
25,
384
],
[
384,
23,
1627
]
],
[
[
581,
25,
351
],
[
351,
62,
1627
]
],
[
[
581,
24,
1593
],
[
1593,
... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisi... | Infliximab may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Infliximab may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interact... |
DB11003 | DB11703 | 748 | 405 | [
"DDInter100",
"DDInter9"
] | Anthrax vaccine | Acalabrutinib | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
748,
24,
405
]
],
[
[
748,
63,
58
],
[
58,
24,
405
]
],
[
[
748,
24,
1619
],
[
1619,
63,
405
]
],
[
[
748,
63,
384
],
[
384,
25,... | [
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
... | Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib ... |
DB08816 | DB11952 | 578 | 800 | [
"DDInter1802",
"DDInter612"
] | Ticagrelor | Duvelisib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
578,
24,
800
]
],
[
[
578,
63,
222
],
[
222,
23,
800
]
],
[
[
578,
63,
310
],
[
310,
24,
800
]
],
[
[
578,
24,
1476
],
[
1476,
6... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazi... |
DB00214 | DB00539 | 1,028 | 11 | [
"DDInter1836",
"DDInter1837"
] | Torasemide | Toremifene | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Moderate | 1 | [
[
[
1028,
24,
11
]
],
[
[
1028,
24,
1376
],
[
1376,
40,
11
]
],
[
[
1028,
18,
3439
],
[
3439,
46,
11
]
],
[
[
1028,
21,
28784
],
[
28784,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Toremifene (Compound)
Torasemide (Compound) downregulates GRN (Gene) and GRN (Gene) is upregulated by Toremifene (Compound)
Torasemide (Compound) causes Thrombocytopenia (S... |
DB00526 | DB10795 | 1,555 | 221 | [
"DDInter1355",
"DDInter1486"
] | Oxaliplatin | Poliovirus type 1 antigen (formaldehyde inactivated) | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
1555,
24,
221
]
],
[
[
1555,
24,
36
],
[
36,
24,
221
]
],
[
[
1555,
64,
581
],
[
581,
24,
221
]
],
[
[
1555,
63,
599
],
[
599,
2... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken w... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Oxaliplatin may lead to a major life threatening interaction when taken w... |
DB00092 | DB09389 | 58 | 517 | [
"DDInter40",
"DDInter1315"
] | Alefacept | Norgestrel | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
58,
24,
517
]
],
[
[
58,
63,
581
],
[
581,
24,
517
]
],
[
[
58,
24,
908
],
[
908,
24,
517
]
],
[
[
58,
25,
1510
],
[
1510,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab... |
DB01001 | DB09352 | 688 | 373 | [
"DDInter1632",
"DDInter892"
] | Salbutamol | Hydroxyamphetamine (ophthalmic) | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | 4-(2-aminopropyl)phenol is a member of amphetamines. | Moderate | 1 | [
[
[
688,
24,
373
]
],
[
[
688,
63,
480
],
[
480,
24,
373
]
],
[
[
688,
24,
659
],
[
659,
24,
373
]
],
[
[
688,
63,
480
],
[
480,
24,... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyamphetamine"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyamphetamine
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyamphet... |
DB00607 | DB06589 | 1,249 | 1,250 | [
"DDInter1256",
"DDInter1400"
] | Nafcillin | Pazopanib | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1249,
24,
1250
]
],
[
[
1249,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
1249,
21,
29203
],
[
29203,
60,
1250
]
],
[
[
1249,
24,
1135
],
[
1... | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Nafcillin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Nafcillin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Nafcillin (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Pazopanib (Compound)
Nafcillin may cause a moderate interaction that could exacer... |
DB00712 | DB00741 | 1,274 | 167 | [
"DDInter763",
"DDInter885"
] | Flurbiprofen | Hydrocortisone | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1274,
24,
167
]
],
[
[
1274,
63,
312
],
[
312,
24,
167
]
],
[
[
1274,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1274,
63,
175
],
[
175,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eplerenone"
],
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone... |
DB00030 | DB00307 | 1,685 | 1,101 | [
"DDInter934",
"DDInter202"
] | Insulin human | Bexarotene | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Moderate | 1 | [
[
[
1685,
24,
1101
]
],
[
[
1685,
24,
609
],
[
609,
62,
1101
]
],
[
[
1685,
24,
362
],
[
362,
23,
1101
]
],
[
[
1685,
24,
915
],
[
915,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin... |
DB00277 | DB00620 | 1,031 | 175 | [
"DDInter1791",
"DDInter1855"
] | Theophylline | Triamcinolone | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Moderate | 1 | [
[
[
1031,
24,
175
]
],
[
[
1031,
24,
1573
],
[
1573,
1,
175
]
],
[
[
1031,
24,
617
],
[
617,
40,
175
]
],
[
[
1031,
5,
11649
],
[
11649,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Triamcinolone (... |
DB00363 | DB01181 | 695 | 1,532 | [
"DDInter419",
"DDInter906"
] | Clozapine | Ifosfamide | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Major | 2 | [
[
[
695,
25,
1532
]
],
[
[
695,
6,
8717
],
[
8717,
45,
1532
]
],
[
[
695,
18,
2976
],
[
2976,
57,
1532
]
],
[
[
695,
64,
1648
],
[
1648,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2A6"
],
[
"CYP2A6",
"{u} (Gene) is bound by {v} (Compound)",
"Ifosfamid... | Clozapine (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Ifosfamide (Compound)
Clozapine (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Ifosfamide (Compound)
Clozapine may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moder... |
DB00087 | DB08895 | 599 | 976 | [
"DDInter41",
"DDInter1825"
] | Alemtuzumab | Tofacitinib | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
599,
25,
976
]
],
[
[
599,
24,
200
],
[
200,
63,
976
]
],
[
[
599,
24,
998
],
[
998,
24,
976
]
],
[
[
599,
24,
652
],
[
652,
64,... | [
[
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"C... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Phenyl... |
DB01030 | DB16582 | 869 | 899 | [
"DDInter1835",
"DDInter1080"
] | Topotecan | Lisocabtagene maraleucel | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has ... | Moderate | 1 | [
[
[
869,
24,
899
]
],
[
[
869,
63,
440
],
[
440,
24,
899
]
],
[
[
869,
24,
810
],
[
810,
24,
899
]
],
[
[
869,
25,
676
],
[
676,
25,... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisocabtagene maraleucel"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Lisocabtagene maraleucel
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Strontium... |
DB00726 | DB00836 | 1,164 | 543 | [
"DDInter1876",
"DDInter1088"
] | Trimipramine | Loperamide | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
1164,
24,
543
]
],
[
[
1164,
1,
675
],
[
675,
24,
543
]
],
[
[
1164,
35,
649
],
[
649,
1,
543
]
],
[
[
1164,
24,
262
],
[
262,
2... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u}... | Trimipramine (Compound) resembles Dextropropoxyphene (Compound) and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Trimipramine (Compound) resembles Clofedanol (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when ... |
DB00912 | DB01032 | 473 | 824 | [
"DDInter1581",
"DDInter1522"
] | Repaglinide | Probenecid | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. | Moderate | 1 | [
[
[
473,
24,
824
]
],
[
[
473,
6,
8374
],
[
8374,
45,
824
]
],
[
[
473,
21,
28722
],
[
28722,
60,
824
]
],
[
[
473,
63,
1274
],
[
1274,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Probenecid"
]
],
[
[
"Repaglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Probenecid (Compound)
Repaglinide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Probenecid (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurb... |
DB00928 | DB11793 | 1,426 | 738 | [
"DDInter148",
"DDInter1297"
] | Azacitidine | Niraparib | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1426,
24,
738
]
],
[
[
1426,
63,
1253
],
[
1253,
24,
738
]
],
[
[
1426,
24,
496
],
[
496,
24,
738
]
],
[
[
1426,
1,
1238
],
[
1238,
... | [
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palifermin"
],
[
... | Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine ... |
DB00047 | DB00635 | 176 | 1,573 | [
"DDInter932",
"DDInter1515"
] | Insulin glargine | Prednisone | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
176,
24,
1573
]
],
[
[
176,
24,
175
],
[
175,
40,
1573
]
],
[
[
176,
23,
1103
],
[
1103,
1,
1573
]
],
[
[
176,
24,
251
],
[
251,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) resembles Predni... |
DB00258 | DB00401 | 666 | 84 | [
"DDInter270",
"DDInter1298"
] | Calcium acetate | Nisoldipine | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Moderate | 1 | [
[
[
666,
24,
84
]
],
[
[
666,
24,
854
],
[
854,
1,
84
]
],
[
[
666,
24,
376
],
[
376,
40,
84
]
],
[
[
666,
21,
28929
],
[
28929,
60,... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nimodipine"
... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Nimodipine and Nimodipine (Compound) resembles Nisoldipine (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine (Compound) resembles Nisoldipine... |
DB01100 | DB04843 | 1,568 | 1,511 | [
"DDInter1470",
"DDInter1149"
] | Pimozide | Mepenzolate | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
1568,
24,
1511
]
],
[
[
1568,
24,
537
],
[
537,
24,
1511
]
],
[
[
1568,
63,
1192
],
[
1192,
24,
1511
]
],
[
[
1568,
1,
1413
],
[
1413,... | [
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopy... |
DB00363 | DB00848 | 695 | 281 | [
"DDInter419",
"DDInter1044"
] | Clozapine | Levamisole | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Major | 2 | [
[
[
695,
25,
281
]
],
[
[
695,
64,
599
],
[
599,
24,
281
]
],
[
[
695,
25,
597
],
[
597,
24,
281
]
],
[
[
695,
24,
126
],
[
126,
24,... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levamisole"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} m... | Clozapine may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Levamisole
Clozapine may lead to a major life threatening interaction when taken with Chloramphenicol and Chloramphenicol may cause a mod... |
DB00365 | DB01024 | 839 | 1,096 | [
"DDInter842",
"DDInter1252"
] | Grepafloxacin | Mycophenolic acid | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
839,
24,
1096
]
],
[
[
839,
24,
1193
],
[
1193,
62,
1096
]
],
[
[
839,
63,
1031
],
[
1031,
23,
1096
]
],
[
[
839,
24,
965
],
[
965,
... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Th... |
DB00619 | DB00959 | 1,419 | 1,486 | [
"DDInter909",
"DDInter1191"
] | Imatinib | Methylprednisolone | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
1419,
24,
1486
]
],
[
[
1419,
24,
175
],
[
175,
40,
1486
]
],
[
[
1419,
24,
167
],
[
167,
1,
1486
]
],
[
[
1419,
63,
251
],
[
251,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Meth... |
DB00446 | DB11988 | 597 | 270 | [
"DDInter351",
"DDInter1321"
] | Chloramphenicol | Ocrelizumab | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
597,
24,
270
]
],
[
[
597,
24,
1060
],
[
1060,
63,
270
]
],
[
[
597,
63,
134
],
[
134,
24,
270
]
],
[
[
597,
24,
1500
],
[
1500,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedot... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken... |
DB00047 | DB00472 | 176 | 758 | [
"DDInter932",
"DDInter758"
] | Insulin glargine | Fluoxetine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Moderate | 1 | [
[
[
176,
24,
758
]
],
[
[
176,
24,
542
],
[
542,
23,
758
]
],
[
[
176,
24,
1148
],
[
1148,
63,
758
]
],
[
[
176,
24,
245
],
[
245,
2... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Fluoxetine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Isopr... |
DB00637 | DB01268 | 1,557 | 1,151 | [
"DDInter128",
"DDInter1731"
] | Astemizole | Sunitinib | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1557,
24,
1151
]
],
[
[
1557,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
1557,
7,
2692
],
[
2692,
45,
1151
]
],
[
[
1557,
7,
9650
],
[
9650,... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Astemizole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Astemizole (Compound) upregulates KIT (Gene) and KIT (Gene) is bound by Sunitinib (Compound)
Astemizole (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Sunitinib (Compound)
Astemizole (Compound) downregul... |
DB00204 | DB11901 | 228 | 913 | [
"DDInter580",
"DDInter107"
] | Dofetilide | Apalutamide | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
228,
25,
913
]
],
[
[
228,
23,
112
],
[
112,
23,
913
]
],
[
[
228,
25,
608
],
[
608,
23,
913
]
],
[
[
228,
64,
600
],
[
600,
24,... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Dofetilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Dofetilide may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause... |
DB01211 | DB14568 | 609 | 982 | [
"DDInter393",
"DDInter1000"
] | Clarithromycin | Ivosidenib | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
609,
25,
982
]
],
[
[
609,
23,
271
],
[
271,
23,
982
]
],
[
[
609,
62,
112
],
[
112,
23,
982
]
],
[
[
609,
63,
168
],
[
168,
23,... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mira... | Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and M... |
DB00477 | DB11827 | 216 | 433 | [
"DDInter363",
"DDInter669"
] | Chlorpromazine | Ertugliflozin | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
216,
24,
433
]
],
[
[
216,
24,
959
],
[
959,
24,
433
]
],
[
[
216,
63,
521
],
[
521,
24,
433
]
],
[
[
216,
35,
820
],
[
820,
24,... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]... | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin an... |
DB00176 | DB00773 | 529 | 896 | [
"DDInter770",
"DDInter702"
] | Fluvoxamine | Etoposide | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Moderate | 1 | [
[
[
529,
24,
896
]
],
[
[
529,
6,
7524
],
[
7524,
45,
896
]
],
[
[
529,
21,
28681
],
[
28681,
60,
896
]
],
[
[
529,
24,
147
],
[
147,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)"... | Fluvoxamine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Etoposide (Compound)
Fluvoxamine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Etoposide (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Vinb... |
DB06043 | DB09074 | 1,644 | 1,362 | [
"DDInter1328",
"DDInter1327"
] | Olaratumab | Olaparib | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Stu... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1644,
24,
1362
]
],
[
[
1644,
63,
1683
],
[
1683,
24,
1362
]
],
[
[
1644,
24,
1531
],
[
1531,
24,
1362
]
],
[
[
1644,
24,
987
],
[
987... | [
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
... | Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canak... |
DB01173 | DB01176 | 358 | 537 | [
"DDInter1349",
"DDInter453"
] | Orphenadrine | Cyclizine | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
358,
24,
537
]
],
[
[
358,
24,
1511
],
[
1511,
63,
537
]
],
[
[
358,
40,
11244
],
[
11244,
1,
537
]
],
[
[
358,
63,
1242
],
[
1242,
... | [
[
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Orphenadrine (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Cyclizine (Comp... |
DB00582 | DB00704 | 1,622 | 267 | [
"DDInter1946",
"DDInter1263"
] | Voriconazole | Naltrexone | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
1622,
24,
267
]
],
[
[
1622,
21,
28695
],
[
28695,
60,
267
]
],
[
[
1622,
63,
522
],
[
522,
24,
267
]
],
[
[
1622,
24,
850
],
[
850,
... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Voriconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is ca... | Voriconazole (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Naltrexone (Compound)
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Nal... |
DB00959 | DB13074 | 1,486 | 877 | [
"DDInter1191",
"DDInter1110"
] | Methylprednisolone | Macimorelin | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
1486,
24,
877
]
],
[
[
1486,
63,
1020
],
[
1020,
24,
877
]
],
[
[
1486,
24,
651
],
[
651,
24,
877
]
],
[
[
1486,
40,
891
],
[
891,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fosphe... |
DB00945 | DB06723 | 1,479 | 115 | [
"DDInter20",
"DDInter58"
] | Acetylsalicylic acid | Aluminum hydroxide | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
1479,
24,
115
]
],
[
[
1479,
63,
1058
],
[
1058,
23,
115
]
],
[
[
1479,
62,
461
],
[
461,
23,
115
]
],
[
[
1479,
24,
1486
],
[
1486,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Moexipril and Moexipril may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with... |
DB01168 | DB11793 | 1,053 | 738 | [
"DDInter1526",
"DDInter1297"
] | Procarbazine | Niraparib | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1053,
24,
738
]
],
[
[
1053,
63,
663
],
[
663,
24,
738
]
],
[
[
1053,
24,
496
],
[
496,
24,
738
]
],
[
[
1053,
64,
770
],
[
770,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Va... |
DB00790 | DB14018 | 664 | 431 | [
"DDInter1431",
"DDInter244"
] | Perindopril | Bromotheophylline | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Bromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome. Bromotheophylline is categorized on the FDA as a ... | Moderate | 1 | [
[
[
664,
24,
431
]
],
[
[
664,
40,
1058
],
[
1058,
24,
431
]
],
[
[
664,
63,
1061
],
[
1061,
24,
431
]
],
[
[
664,
1,
954
],
[
954,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromotheophylline"
]
],
[
[
"Perindopril",
"{u} (Compound) resembles {v} (Compound)",
"Moexipril"
],
[
"Moexipril",
"{u} may cause a ... | Perindopril (Compound) resembles Moexipril (Compound) and Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Bromotheophylline
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction... |
DB01059 | DB08865 | 956 | 1,593 | [
"DDInter1313",
"DDInter448"
] | Norfloxacin | Crizotinib | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
956,
25,
1593
]
],
[
[
956,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
956,
6,
3199
],
[
3199,
57,
1593
]
],
[
[
956,
18,
7744
],
[
7744,
... | [
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Norfloxacin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizo... | Norfloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Norfloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Crizotinib (Compound)
Norfloxacin (Compound) downregulates PRR7 (Gene) and PRR7 (Gene) is downregulated by Crizotinib (Compound)
Norfloxacin (Comp... |
DB06077 | DB13928 | 879 | 1,385 | [
"DDInter1102",
"DDInter1660"
] | Lumateperone | Semaglutide | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
879,
24,
1385
]
],
[
[
879,
25,
1476
],
[
1476,
24,
1385
]
],
[
[
879,
63,
1144
],
[
1144,
24,
1385
]
],
[
[
879,
24,
1296
],
[
1296,
... | [
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Briga... | Lumateperone may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may... |
DB00590 | DB11921 | 1,433 | 1,019 | [
"DDInter592",
"DDInter492"
] | Doxazosin | Deflazacort | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfi... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
1433,
24,
1019
]
],
[
[
1433,
24,
1344
],
[
1344,
24,
1019
]
],
[
[
1433,
24,
159
],
[
159,
63,
1019
]
],
[
[
1433,
1,
1205
],
[
1205,... | [
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
... | Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib an... |
DB00980 | DB12500 | 969 | 283 | [
"DDInter1564",
"DDInter714"
] | Ramelteon | Fedratinib | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
969,
24,
283
]
],
[
[
969,
63,
1419
],
[
1419,
24,
283
]
],
[
[
969,
24,
401
],
[
401,
24,
283
]
],
[
[
969,
24,
159
],
[
159,
6... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazi... |
DB01101 | DB10316 | 60 | 334 | [
"DDInter285",
"DDInter1248"
] | Capecitabine | Mumps virus strain B level jeryl lynn live antigen | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
60,
25,
334
]
],
[
[
60,
64,
1057
],
[
1057,
25,
334
]
],
[
[
60,
63,
328
],
[
328,
25,
334
]
],
[
[
60,
25,
908
],
[
908,
25,
... | [
[
[
"Capecitabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Capecitabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Capecitabine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Mercapt... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.